Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Sanofi: Trump's Vaccine Policy Won't Break The Story
24.08.2026 08:52
Sanofi stock faces temporary pressure after Trumpâs vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
20.08.2026 14:21
Alvotech stock outlook: Hold rating after missed H1 2026 earnings and FDA CRLs; biosimilar pipeline targets Q4 2026. Click for this ALVO update.
Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage
20.08.2026 06:33
Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after his daughter's near-fatal hemorrhage.
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
07.08.2026 14:46
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
CytomX Therapeutics Q2 Earnings Call Highlights
07.08.2026 01:03
CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv
Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock
05.08.2026 16:20
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
05.08.2026 15:49
RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.
REGN or INCY: Which Is the Better Value Stock Right Now?
05.08.2026 15:40
REGN vs. INCY: Which Stock Is the Better Value Option?
REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance
01.08.2026 02:03
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.
Regeneron (REGN) Q2 2026 Earnings Call Transcript
31.07.2026 01:02
Revenue surged 17% as Dupixent and EYLEA HD posted record sales.
Why Regeneron (REGN) Is Up 6.7% After Mixed Q2 Results And New Telix Oncology Deal
30.07.2026 15:12
Regeneron Pharmaceuticals reported past second-quarter 2026 results with revenue rising to US$4,290.7 million from US$3,675.6 million a year earlier, while net income slipped to US$1,296.9 million and diluted EPS from continuing operations softened to US$12.23. Alongside these mixed earnings, Regeneron recently entered a collaboration with Telix Pharmaceuticals to co-develop next-generation radiopharmaceutical oncology therapies, potentially broadening its precision-medicine footprint beyond...
Regeneron (REGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
30.07.2026 14:30
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Regeneron Beats Second-Quarter Expectations as Dupixent Growth Fuels Strong Results
30.07.2026 14:00
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported stronger-than-expected second-quarter results, comfortably surpassing Wall Street forecasts for both earnings and revenue.
Regeneron (REGN) Q2 Earnings and Revenues Top Estimates
30.07.2026 12:05
Regeneron (REGN) delivered earnings and revenue surprises of +42.90% and +11.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Regeneron Pharmaceuticals (NASDAQ:REGN) Surges After Crushing Q2 Estimates with Revenue and EPS Beat
30.07.2026 11:31
Regeneron (REGN) crushed Q2 estimates with $4.29B revenue and $14.29 EPS, driven by Dupixent and EYLEA HD growth, sending shares higher.
Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales
30.07.2026 11:19
Biotech company Regeneron (NASDAQ:REGN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.
Regeneron Reports Second Quarter 2026 Financial and Operating Results
30.07.2026 10:30
Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025Dupixent® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD® U.S. net sales increased 52% to a new all-time high of $596 millionLibtayo® global net sales increased 30% to a new all-time high of $489 millionGAAP EPS of $12.23, including $1.02 negative impact from IPR&D non-GAAP EPS(a) of $14.29, including $0.99 negative impact from IPR&DSanofi Development Balance
How Telix landed a $2.1 billion radiopharma deal with Regeneron
30.07.2026 09:12
Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.
Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs
28.07.2026 13:44
Outlook Therapeutics, Inc. wins FDA & EU approval for LYTENAVA for wet AMD, but cash burn and competition loom. Click for this OTLK update.
Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?
28.07.2026 13:41
Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.